Stella Pharma Corporation (TYO:4888)
470.00
+1.00 (0.21%)
At close: Mar 6, 2026
Stella Pharma Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Cash & Equivalents | 2,691 | 3,206 | 2,052 | 2,710 | 3,276 | 1,251 |
Short-Term Investments | - | - | 300 | - | - | - |
Cash & Short-Term Investments | 2,691 | 3,206 | 2,352 | 2,710 | 3,276 | 1,251 |
Cash Growth | -22.05% | 36.31% | -13.21% | -17.28% | 161.87% | -37.67% |
Accounts Receivable | 572 | 714 | 76 | 59 | 16 | 55 |
Receivables | 572 | 714 | 76 | 59 | 16 | 55 |
Inventory | 1,216 | 1,230 | 1,116 | 940 | 773 | 392 |
Prepaid Expenses | 79 | 49 | 40 | 39 | 36 | 40 |
Other Current Assets | 79 | 44 | 45 | 44 | 74 | 72 |
Total Current Assets | 4,637 | 5,243 | 3,629 | 3,792 | 4,175 | 1,810 |
Property, Plant & Equipment | 50 | 66 | 81 | 102 | 92 | 68 |
Long-Term Investments | 44 | 57 | 57 | 371 | 382 | 89 |
Other Intangible Assets | 44 | 49 | 52 | 61 | 68 | 79 |
Other Long-Term Assets | 1 | 2 | 1 | 3 | 1 | 2 |
Total Assets | 4,776 | 5,417 | 3,820 | 4,329 | 4,718 | 2,048 |
Accounts Payable | 1 | 22 | 75 | 49 | 48 | 62 |
Accrued Expenses | 12 | 7 | 4 | 6 | 2 | 47 |
Current Portion of Long-Term Debt | 158 | 158 | 160 | 160 | 160 | 160 |
Current Income Taxes Payable | 66 | 197 | 212 | 202 | 92 | 45 |
Other Current Liabilities | 10 | 6 | 4 | 4 | 6 | 5 |
Total Current Liabilities | 247 | 390 | 455 | 421 | 308 | 319 |
Long-Term Debt | 628 | 608 | 773 | 933 | 1,093 | 1,253 |
Pension & Post-Retirement Benefits | 62 | 59 | 53 | 47 | 51 | 46 |
Other Long-Term Liabilities | 1,144 | 1,153 | 163 | 176 | 187 | 200 |
Total Liabilities | 2,081 | 2,210 | 1,444 | 1,577 | 1,639 | 1,818 |
Common Stock | 2,859 | 2,859 | 2,938 | 3,300 | 3,808 | 1,999 |
Additional Paid-In Capital | 348 | 489 | 195 | 220 | 1,908 | 99 |
Retained Earnings | -512 | -140 | -763 | -778 | -2,636 | -1,869 |
Comprehensive Income & Other | - | -1 | 6 | 10 | -1 | 1 |
Shareholders' Equity | 2,695 | 3,207 | 2,376 | 2,752 | 3,079 | 230 |
Total Liabilities & Equity | 4,776 | 5,417 | 3,820 | 4,329 | 4,718 | 2,048 |
Total Debt | 786 | 766 | 933 | 1,093 | 1,253 | 1,413 |
Net Cash (Debt) | 1,905 | 2,440 | 1,419 | 1,617 | 2,023 | -162 |
Net Cash Growth | -27.81% | 71.95% | -12.25% | -20.07% | - | - |
Net Cash Per Share | 55.99 | 73.10 | 45.81 | 56.00 | 72.04 | -8.09 |
Filing Date Shares Outstanding | 34.02 | 34.02 | 31.22 | 29.48 | 28.65 | 20.14 |
Total Common Shares Outstanding | 34.02 | 34.02 | 31.22 | 29.48 | 28.65 | 20.14 |
Working Capital | 4,390 | 4,853 | 3,174 | 3,371 | 3,867 | 1,491 |
Book Value Per Share | 79.21 | 94.27 | 76.10 | 93.35 | 107.48 | 11.42 |
Tangible Book Value | 2,651 | 3,158 | 2,324 | 2,691 | 3,011 | 151 |
Tangible Book Value Per Share | 77.92 | 92.83 | 74.43 | 91.28 | 105.10 | 7.50 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.